Literature DB >> 2447417

Effects of nicorandil on coronary hemodynamics in ischemic heart disease: comparison with nitroglycerin, nifedipine, and propranolol.

K Kobayashi1, T Hakuta.   

Abstract

Effects of nicorandil (NC), a newly synthesized nicotinamide derivative (2 mg i.v.), nitroglycerin (TNG, 0.3 mg sublingual), nifedipine (NF, 10 mg sublingual), and propranolol (PR, 0.1 mg/kg i.v.) on coronary hemodynamics were evaluated in 41 patients with ischemic heart disease. Coronary sinus flow (CSF) was measured using a continuous thermodilution method. NC decreased arterial pressure, cardiac output (CO), and pulmonary artery pressure without changing heart rate. Rate-pressure product tended to decrease. Resting CSF was increased by NC (117-148 ml/min, p less than 0.01) and NF. TNG and PR caused no significant changes. Furthermore, NC revealed the highest CSF/CO ratio among four agents and decreased coronary resistance. During rapid atrial pacing, CSF was slightly increased by TNG, but remained unchanged after NC and NF. Myocardial norepinephrine release was markedly increased by TNG (1.5-6.2 ng/min, p less than 0.01) and slightly increased by NF. No changes were noted after NC and PR. Myocardial lactate extraction varied insignificantly in all agents. NC is a potent coronary vasodilator and seems to reduce both preload and afterload; however, in contrast to TNG and NF, NC did not cause reflex tachycardia or an increase of myocardial sympathetic tone.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2447417

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Double-blind comparison of the acute effects of two relevant doses of oral nicorandil on central hemodynamics, left ventricular function, and myocardial contractility.

Authors:  A Baumbach; U Braun; G Döring; K K Haase; W Voelker; K R Karsch
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

2.  A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris.

Authors:  S Di Somma; V Liguori; M Petitto; A Carotenuto; D Bokor; O de Divitiis; M de Divitiis
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

3.  Pharmacokinetics of nicorandil in patients with normal and impaired renal function.

Authors:  M Molinaro; G Villa; M B Regazzi; A Salvadeo; S Segagni; R Rondanelli; E Sartirana
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 4.  Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.

Authors:  J Frampton; M M Buckley; A Fitton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

5.  Nicorandil suppressed myocardial purine metabolism during exercise in patients with angina pectoris.

Authors:  K Ogino; S Osaki; N Noguchi; H Kitamura; H Omodani; M Kato; I Hisatome; T Matsumoto; T Kinugawa; H Miyakoda
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

6.  Coronary effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs.

Authors:  K Hashimoto; M Kinoshita; Y Ohbayashi
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.